European Companies Search Engine
EU funding (€5,839,656): InSilc: In-silico trials for drug-eluting BVS design, development and evaluation Hor 1 Nov 2017 EU Research and Innovation programme "Horizon"
Overview
Text
InSilc: In-silico trials for drug-eluting BVS design, development and evaluation
The aim of InSilc is to develop an in-silico clinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS), by building on the comprehensive biological and biomedical knowledge and advanced modelling approaches to simulate their implantation performance in the individual cardiovascular physiology. The InSilc platform is based on the extension of existing multidisciplinary and multiscale models for simulating the drug-eluting BVS mechanical behaviour, the deployment and degradation, the fluid dynamics in the micro- and macroscale, and the myocardial perfusion, for predicting its interaction with the vascular wall in the short- and medium/long term. InSilc goes beyond the design and development of ISCT and lays on the generation of in-silico models for obtaining quick and informed answers to several “What if” scenarios. “Virtual” patients would be given a “virtual” drug-eluting BVS, for observing the performance of the scaffold, assess and quantify the intended effect, with a deeper understanding than normal trials can provide. By integrating the information obtained from different in-silico predictive models, InSilc will: (i) assist in the development, assessment and optimization of the drug-eluting BVS and deliver accurate and reliable information to the Stent Biomedical Industry, (ii) assist the interventional Cardiologists in improving the surgical process of drug-eluting BVS implantation, support them in the clinical assessment and reduce the complications of suboptimal scaffold performance. By introducing computer simulations for establishing the safety and efficacy of drug-eluting BVS, InSilc aims to lower development costs and shorten time-to-market, reduce, refine, and partially replace human clinical trials through a more effective human clinical trials design, reduce the need for animal testing and result in a significant reduction of the associated direct and indirect costs.
Funded Companies:
| Company name | Funding amount |
| Boston Scientific Ltd. | €305,580 |
| Cbset Inc. | €503,212 |
| Consiglio Nazionale Delle Ricerche | €343,705 |
| Erasmus Universitair Medisch Centrum Rotterdam | €805,580 |
| Feops | €409,330 |
| Idryma Technologias Kai Erevnas | €822,366 |
| Istrazivacko Razvojni Centar ZA Bioinzenjering Bioirc d.o.o. | €363,080 |
| Mediolanum Cardio Research Srl | €259,330 |
| Panepistimio Ioanninon | €200,605 |
| Politecnico Di Milano | €603,130 |
| The University of Sheffield | €98,000 |
| University of Galway | €566,155 |
| University of Leeds | €559,580 |
Source: https://cordis.europa.eu/project/id/777119
The filing refers to a past date, and does not necessarily reflect the current state.